The board of directors of Mabpharm Limited announced that the new drug application of CMAB008 Lei Ting® (infliximab for injection), a core product of the Company and a recombinant anti-tumor necrosis factora ("TNFa") human- mouse chimeric monoclonal antibody independently developed by the Company, was recently approved by the Ministry of Health of Peru (Ministerio de Salud) for the treatment of: (i) ulcerative colitis in adults; (ii) ankylosing spondylitis; (iii) rheumatoid arthritis; (iv) Crohn's disease in adults and pediatric patients aged above 6 years old; (v) fistula Crohn's disease; and (vi) psoriasis. CMAB008 is the first infliximab developed in the People's Republic of China (the "PRC") and approved for marketing, which is a monoclonal antibody biosimilar independently developed by the Company and a core product of the Company. CMAB008 uses the Chinese hamster ovary cell expression system, and is a monoclonal antibody targeting TNF that specifically merges with TNF and blocks the inflammatory cascade response caused by TNF; it is mainly used for treatment of ulcerative colitis in adults, ankylosing spondylitis, Crohn's disease in adults and pediatric patients aged above 6 years old, fistula Crohn's disease, rheumatoid arthritis and psoriasis.

The researches they have completed have shown that, compared to other anti-TNF drugs on the market, CMAB008 (infliximab for injection) has a stronger affinity for TNF and a stronger glycosylation character, with rapid onset of effect, long-lasting efficacy, long dosing intervals and no hypersensitivity reactions. The results of completed researches including, clinical trials, non-clinical comparative studies, and pharmacological comparisons of CMAB008 have also shown that CMAB008 is identical to the original infliximab in terms of efficacy, safety, pharmacological profile and quality. The antibody drug production base of Taizhou Mabtech Pharmaceutical Limited under the Company in China Medical City, Taizhou, Jiangsu Province also successfully passed the good manufacturing practices ("GMP") compliance inspection for CMAB008 by Jiangsu Provincial Drug Administration.

Infliximab is included in the PRC's basic medical insurance program (the "Medical Insurance") drug catalogue, and in accordance with relevant regulations on Medical Insurance of the PRC, CMAB008 is applicable to the Medical Insurance coverage of infliximab, thus providing a new and more economical and affordable option for patients.